Fresh analysis suggests that individuals who stop using new GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass far faster than those who stop traditional diet and exercise plans.
Findings released in a prominent health publication demonstrates that while obese people can lose a large proportion of their total mass while on the medication, the weight comes back at an average rate of 0.8 kg per month after stopping.
"Individuals using such medications should be informed of the potential of quick rebound weight gain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to pre-treatment weight in about a year and a half.
Comparing Approaches
The analysis, which reviewed dozens of trials involving thousands of patients, compared the results of the injectable medications with other pills.
Researchers emphasize that people who lose weight through dieting generally see a slower weight regain—perhaps 0.1 kg a month—once they finish.
The Reason for the Rapid Rebound
Nutrition scientists believe the mode of action of the jabs is key to understanding the amplified weight return.
GLP-1 drugs mimic a natural hormone called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its endogenous hormone, and could reduce responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement leads to hunger is uncontrolled, making excessive eating far more likely."
A Chronic Issue?
Health authorities suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts contend that, due to the high risk of relapse, the treatment might need to be ongoing.
This perspective is supported by drug manufacturers, who state that the results "emphasize the persistent character of obesity," comparing it to managing conditions like diabetes.
User Experiences
Individuals who have stopped the medication describe a powerful resurgence of hunger.
"I experienced something that goes on and I was suddenly starving," recalled an individual.
This difficulty is compounded if individuals have not adopted permanent dietary or behavioural modifications during therapy.
Growing Interest
Figures indicate that millions of adults in the UK have tried these injections in the past year, with interest remaining high.
- Use is greater among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, researchers caution that while the jabs are effective agents for weight loss, they are not a standalone fix and maintained weight loss relies on integrated lifestyle changes.
